Reviewed, UniProtKB/Swiss-Prot P09086 (PO2F2_HUMAN)

Names and origin

Protein names

Recommended name:
    POU domain, class 2, transcription factor 2
Alternative name(s):
    Octamer-binding transcription factor 2
      Short name=Oct-2
      Short name=OTF-2
    Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2

Gene names

Name:	POU2F2
Synonyms:	OCT2, OTF2

Organism

Homo sapiens (Human) [Complete proteome]

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Protein attributes

Sequence length	479 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is further processed into a mature form.
Protein existence	Evidence at protein level.

General annotation (Comments)

Function	Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Isoform 5 activates the U2 small nuclear RNA (snRNA) promoter. Ref.2 Ref.6 Ref.8 Ref.9
Subunit structure	Interacts with NR3C1, AR and PGR. Ref.11
Subcellular location	Cytoplasm By similarity. Nucleus.
Tissue specificity	Isoform 3 is B-cell specific. Isoform 5 is expressed in B-cells and the immunoglobulin-expressing T-cell line Molt-4, but not in the T-cell line BW 5147. Ref.2 Ref.10
Sequence similarities	Belongs to the POU transcription factor family. Class-2 subfamily. Contains 1 homeobox DNA-binding domain. Contains 1 POU-specific domain.

Ontologies

Keywords
Biological process	Transcription Transcription regulation
Cellular component	Cytoplasm Nucleus
Coding sequence diversity	Alternative splicing
Domain	Homeobox
Ligand	DNA-binding
Molecular function	Activator
PTM	Phosphoprotein
Technical term	3D-structure Complete proteome
Gene Ontology (GO)
Biological process	humoral immune response Traceable author statement. Source: ProtInc regulation of transcription, DNA-dependent Inferred from electronic annotation. Source: InterPro transcription from RNA polymerase II promoter Traceable author statement. Source: ProtInc
Cellular component	cytoplasm Inferred from electronic annotation. Source: UniProtKB-SubCell nucleus Inferred from direct assay. Source: MGI
Molecular function	sequence-specific DNA binding Inferred from direct assay. Source: MGI transcription factor activity Traceable author statement. Source: ProtInc
Complete GO annotation...

Alternative products

This entry describes 5 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: P09086-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: P09086-2)

The sequence of this isoform differs from the canonical sequence as follows:
     468-479: Missing.

Isoform 3 (identifier: P09086-3)

The sequence of this isoform differs from the canonical sequence as follows:
     168-183: Missing.

Isoform 4 (identifier: P09086-4)

The sequence of this isoform differs from the canonical sequence as follows:
     168-183: Missing.
     400-416: VTTLSSAVGTLHPSRTA → AQTPALKAATRLSACQA
     417-479: Missing.

Isoform 5 (identifier: P09086-5)

Also known as: Oct-2B;

The sequence of this isoform differs from the canonical sequence as follows:
     468-479: PGLWWNPAPYQP → STMVGLSSGL...GGPEAGSKAE

Note: Incomplete sequence.

Sequence annotation (Features)

Feature key

Position(s)

Length

Description

Graphical view

Feature identifier

Molecule processing

Initiator methionine

1

1

Removed

Chain

2 – 479

478

POU domain, class 2, transcription factor 2

PRO_0000100714

Regions

Domain

195 – 269

75

POU-specific

Domain

389 – 410

22

Leucine-zipper

DNA binding

297 – 356

60

Homeobox

Compositional bias

417 – 424

8

Gly-rich

Amino acid modifications

Modified residue

250

1

Phosphoserine Ref.12

Natural variations

Alternative sequence

168 – 183

16

Missing in isoform 3 and isoform 4.

VSP_002324

Alternative sequence

400 – 416

17

VTTLS…PSRTA → AQTPALKAATRLSACQA in isoform 4.

VSP_007848

Alternative sequence

417 – 479

63

Missing in isoform 4.

VSP_007849

Alternative sequence

468 – 479

12

Missing in isoform 2.

VSP_002325

Alternative sequence

468 – 479

12

PGLWW…APYQP → STMVGLSSGLSPALMSNNPL ATIQALASGGTLPLTSLDGS GNLVLGAAGAAPGSPSLVTS PLFLNHTGLPLLSAPPGVGL VSAAAAAVAASISSKSPGLS SSSSSSSSSSSSTCSDVAAQ TPGGPGGPEAGSKAE in isoform 5.

VSP_032187

Experimental info

Mutagenesis

340 – 342

3

VIR → FNP: Suppresses DNA-binding ability.

Secondary structure

1

.

.

.

.

.

.

.

.

.

.

479

Helix Strand Turn

Details...

Helix

307 – 318

12

Helix

324 – 331

8

Turn

332 – 335

4

Helix

338 – 350

13

Turn

356 – 358

3

Sequences

	Sequence		Length	Mass (Da)
	Isoform 1 [UniParc]. Last modified January 23, 2007. Version 3. Checksum: 8DA661DC07644D43	FASTA	479	51,209
	10 20 30 40 50 60 MVHSSMGAPE IRMSKPLEAE KQGLDSPSEH TDTERNGPDT NHQNPQNKTS PFSVSPTGPS 70 80 90 100 110 120 TKIKAEDPSG DSAPAAPLPP QPAQPHLPQA QLMLTGSQLA GDIQQLLQLQ QLVLVPGHHL 130 140 150 160 170 180 QPPAQFLLPQ AQQSQPGLLP TPNLFQLPQQ TQGALLTSQP RAGLPTQAVT RPTLPDPHLS 190 200 210 220 230 240 HPQPPKCLEP PSHPEEPSDL EELEQFARTF KQRRIKLGFT QGDVGLAMGK LYGNDFSQTT 250 260 270 280 290 300 ISRFEALNLS FKNMCKLKPL LEKWLNDAET MSVDSSLPSP NQLSSPSLGF DGLPGRRRKK 310 320 330 340 350 360 RTSIETNVRF ALEKSFLANQ KPTSEEILLI AEQLHMEKEV IRVWFCNRRQ KEKRINPCSA 370 380 390 400 410 420 APMLPSPGKP ASYSPHMVTP QGGAGTLPLS QASSSLSTTV TTLSSAVGTL HPSRTAGGGG 430 440 450 460 470 GGGGAAPPLN SIPSVTPPPP ATTNSTNPSP QGSHSAIGLS GLNPSTGPGL WWNPAPYQP
	Isoform 2. Checksum: 444B5AB65B950050	FASTA	467	49,801
	10 20 30 40 50 60 MVHSSMGAPE IRMSKPLEAE KQGLDSPSEH TDTERNGPDT NHQNPQNKTS PFSVSPTGPS 70 80 90 100 110 120 TKIKAEDPSG DSAPAAPLPP QPAQPHLPQA QLMLTGSQLA GDIQQLLQLQ QLVLVPGHHL 130 140 150 160 170 180 QPPAQFLLPQ AQQSQPGLLP TPNLFQLPQQ TQGALLTSQP RAGLPTQAVT RPTLPDPHLS 190 200 210 220 230 240 HPQPPKCLEP PSHPEEPSDL EELEQFARTF KQRRIKLGFT QGDVGLAMGK LYGNDFSQTT 250 260 270 280 290 300 ISRFEALNLS FKNMCKLKPL LEKWLNDAET MSVDSSLPSP NQLSSPSLGF DGLPGRRRKK 310 320 330 340 350 360 RTSIETNVRF ALEKSFLANQ KPTSEEILLI AEQLHMEKEV IRVWFCNRRQ KEKRINPCSA 370 380 390 400 410 420 APMLPSPGKP ASYSPHMVTP QGGAGTLPLS QASSSLSTTV TTLSSAVGTL HPSRTAGGGG 430 440 450 460 GGGGAAPPLN SIPSVTPPPP ATTNSTNPSP QGSHSAIGLS GLNPSTG
	Isoform 3. Checksum: 5DCCA37A76A65AB9	FASTA	463	49,461
	10 20 30 40 50 60 MVHSSMGAPE IRMSKPLEAE KQGLDSPSEH TDTERNGPDT NHQNPQNKTS PFSVSPTGPS 70 80 90 100 110 120 TKIKAEDPSG DSAPAAPLPP QPAQPHLPQA QLMLTGSQLA GDIQQLLQLQ QLVLVPGHHL 130 140 150 160 170 180 QPPAQFLLPQ AQQSQPGLLP TPNLFQLPQQ TQGALLTSQP RAGLPTQPPK CLEPPSHPEE 190 200 210 220 230 240 PSDLEELEQF ARTFKQRRIK LGFTQGDVGL AMGKLYGNDF SQTTISRFEA LNLSFKNMCK 250 260 270 280 290 300 LKPLLEKWLN DAETMSVDSS LPSPNQLSSP SLGFDGLPGR RRKKRTSIET NVRFALEKSF 310 320 330 340 350 360 LANQKPTSEE ILLIAEQLHM EKEVIRVWFC NRRQKEKRIN PCSAAPMLPS PGKPASYSPH 370 380 390 400 410 420 MVTPQGGAGT LPLSQASSSL STTVTTLSSA VGTLHPSRTA GGGGGGGGAA PPLNSIPSVT 430 440 450 460 PPPPATTNST NPSPQGSHSA IGLSGLNPST GPGLWWNPAP YQP
	Isoform 4. Checksum: 074B384660350FCE	FASTA	400	43,528
	10 20 30 40 50 60 MVHSSMGAPE IRMSKPLEAE KQGLDSPSEH TDTERNGPDT NHQNPQNKTS PFSVSPTGPS 70 80 90 100 110 120 TKIKAEDPSG DSAPAAPLPP QPAQPHLPQA QLMLTGSQLA GDIQQLLQLQ QLVLVPGHHL 130 140 150 160 170 180 QPPAQFLLPQ AQQSQPGLLP TPNLFQLPQQ TQGALLTSQP RAGLPTQPPK CLEPPSHPEE 190 200 210 220 230 240 PSDLEELEQF ARTFKQRRIK LGFTQGDVGL AMGKLYGNDF SQTTISRFEA LNLSFKNMCK 250 260 270 280 290 300 LKPLLEKWLN DAETMSVDSS LPSPNQLSSP SLGFDGLPGR RRKKRTSIET NVRFALEKSF 310 320 330 340 350 360 LANQKPTSEE ILLIAEQLHM EKEVIRVWFC NRRQKEKRIN PCSAAPMLPS PGKPASYSPH 370 380 390 400 MVTPQGGAGT LPLSQASSSL STTAQTPALK AATRLSACQA
	Isoform 5 (Oct-2B). Checksum: F5E4E2B0D206FC15	FASTA	602	62,172
	10 20 30 40 50 60 MVHSSMGAPE IRMSKPLEAE KQGLDSPSEH TDTERNGPDT NHQNPQNKTS PFSVSPTGPS 70 80 90 100 110 120 TKIKAEDPSG DSAPAAPLPP QPAQPHLPQA QLMLTGSQLA GDIQQLLQLQ QLVLVPGHHL 130 140 150 160 170 180 QPPAQFLLPQ AQQSQPGLLP TPNLFQLPQQ TQGALLTSQP RAGLPTQAVT RPTLPDPHLS 190 200 210 220 230 240 HPQPPKCLEP PSHPEEPSDL EELEQFARTF KQRRIKLGFT QGDVGLAMGK LYGNDFSQTT 250 260 270 280 290 300 ISRFEALNLS FKNMCKLKPL LEKWLNDAET MSVDSSLPSP NQLSSPSLGF DGLPGRRRKK 310 320 330 340 350 360 RTSIETNVRF ALEKSFLANQ KPTSEEILLI AEQLHMEKEV IRVWFCNRRQ KEKRINPCSA 370 380 390 400 410 420 APMLPSPGKP ASYSPHMVTP QGGAGTLPLS QASSSLSTTV TTLSSAVGTL HPSRTAGGGG 430 440 450 460 470 480 GGGGAAPPLN SIPSVTPPPP ATTNSTNPSP QGSHSAIGLS GLNPSTGSTM VGLSSGLSPA 490 500 510 520 530 540 LMSNNPLATI QALASGGTLP LTSLDGSGNL VLGAAGAAPG SPSLVTSPLF LNHTGLPLLS 550 560 570 580 590 600 APPGVGLVSA AAAAVAASIS SKSPGLSSSS SSSSSSSSST CSDVAAQTPG GPGGPEAGSK AE

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains." Clerc R.G., Corcoran L.M., Lebowitz J.H., Baltimore D., Sharp P.A. Genes Dev. 2:1570-1581(1988) [PubMed: 3265124] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF 450-479 (ISOFORM 1).
[2]	"A human lymphoid-specific transcription factor that activates immunoglobulin genes is a homoeobox protein." Scheidereit C., Cromlish J.A., Gerster T., Kawakami K., Balmaceda C.-G., Currie R.A., Roder R.G. Nature 336:551-557(1988) [PubMed: 2904654] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, TISSUE SPECIFICITY. Tissue: B-cell lymphoma.
[3]	"Cloning of human full-length CDSs in BD Creator(TM) system donor vector." Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., Phelan M., Farmer A. Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
[4]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). Tissue: Lymph.
[5]	"A cloned octamer transcription factor stimulates transcription from lymphoid-specific promoters in non-B cells." Mueller M.M., Ruppert S., Schaffner W., Matthias P. Nature 336:544-551(1988) [PubMed: 2904653] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 2-479 (ISOFORM 1). Tissue: B-cell.
[6]	"Transcription factor Oct-2A contains functionally redundant activating domains and works selectively from a promoter but not from a remote enhancer position in non-lymphoid (HeLa) cells." Muller-Immergluck M.M., Schaffner W., Matthias P. EMBO J. 9:1625-1634(1990) [PubMed: 2328728] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 99-161, FUNCTION.
[7]	"Short introns interrupting the Oct-2 POU domain may prevent recombination between POU family genes without interfering with potential POU domain 'shuffling' in evolution." Matsuo K., Clay O., Kuenzler P., Georgiev O., Urbanek P., Schaffner W. Biol. Chem. Hoppe-Seyler 375:675-683(1994) [PubMed: 7888080] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 168-377.
[8]	"A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain." Ko H.-S., Fast P., McBride W., Staudt L.M. Cell 55:135-144(1988) [PubMed: 2901913] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 240-387, FUNCTION.
[9]	"Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter." Tanaka M., Lai J.-S., Herr W. Cell 68:755-767(1992) [PubMed: 1739980] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 468-479 (ISOFORM 5), FUNCTION.
[10]	"Identification of a novel lymphoid specific octamer binding protein (OTF-2B) by proteolytic clipping bandshift assay (PCBA)." Schreiber E., Matthias P., Mueller M.M., Schaffner W. EMBO J. 7:4221-4229(1988) [PubMed: 3072196] [Abstract] Cited for: IDENTIFICATION (ISOFORM 5), TISSUE SPECIFICITY.
[11]	"Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter." Prefontaine G.G., Walther R., Giffin W., Lemieux M.E., Pope L., Hache R.J.G. J. Biol. Chem. 274:26713-26719(1999) [PubMed: 10480874] [Abstract] Cited for: INTERACTION WITH NR3C1; AR AND PGR.
[12]	"A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed: 18669648] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-250, MASS SPECTROMETRY.
[13]	"Solution structure of a POU-specific homeodomain: 3D-NMR studies of human B-cell transcription factor Oct-2." Sivaraja M., Botfield M.C., Mueller M., Jancso A., Weiss M.A. Biochemistry 33:9845-9855(1994) [PubMed: 7914745] [Abstract] Cited for: STRUCTURE BY NMR OF 297-359.
+	Additional computationally mapped references.

Cross-references

Sequence databases

EMBLGenBankDDBJ

M36653 mRNA. Translation: AAA36389.1.
X53468 mRNA. Translation: CAA37562.1.
X53469 mRNA. Translation: CAA37565.1.
M36542 mRNA. Translation: AAA36732.1.
X13810 mRNA. Translation: CAA32040.1.
BT007438 mRNA. Translation: AAP36106.1.
BC006101 mRNA. Translation: AAH06101.1.
M36718 mRNA. Translation: AAA59978.1.
X13809 mRNA. Translation: CAA32039.1. Different initiation.
X81030 Genomic DNA. Translation: CAA56933.1.

IPI

IPI00002666.
IPI00012533.
IPI00221055.
IPI00335926.
IPI00888702.

PIR

A31753.
A42098.

RefSeq

NP_002689.1.

UniGene

Hs.654420

3D structure databases

PDBPDBe

Entry	Method	Resolution (Å)	Chain	Positions	PDBsum
1HDP	NMR	-	A	297-359	[»]

SMR

P09086. Positions 199-357.

ModBase

Search...

Protein-protein interaction databases

DIP

DIP:51N.

STRING

P09086.

PTM databases

PhosphoSite

P09086.

Proteomic databases

PRIDE

P09086.

Genome annotation databases

Ensembl

ENST00000292077; ENSP00000292077; ENSG00000028277; Homo sapiens. [Genome view]
ENST00000342301; ENSP00000339369; ENSG00000028277; Homo sapiens. [Genome view]
ENST00000389341; ENSP00000373992; ENSG00000028277; Homo sapiens. [Genome view]

GeneID

5452.

KEGG

hsa:5452.

UCSC

uc002osn.1. human.
uc002osp.1. human.
uc002osq.1. human.

Organism-specific databases

CTD

5452.

GeneCards

GC19M047286.

H-InvDB

HIX0015168.

HGNC

HGNC:9213. POU2F2.

HPA

CAB002513.

MIM

164176. gene.

PharmGKB

PA33537.

GenAtlas

Search...

Phylogenomic databases

HOGENOM

P09086.

HOVERGEN

P09086.

OMA

LFLNHTG.

Enzyme and pathway databases

Pathway_Interaction_DB

bcr_5pathway. BCR signaling pathway.

Gene expression databases

ArrayExpress

P09086.

Bgee

P09086.

CleanEx

HS_POU2F2.

Genevestigator

P09086.

GermOnline

ENSG00000028277. Homo sapiens.

Family and domain databases

InterPro

IPR001356. Homeobox.
IPR017970. Homeobox_CS.
IPR012287. Homeodomain-rel.
IPR013847. POU.
IPR000327. POU_specific.
IPR000972. TF_octamer_bd.
[Graphical view]

Gene3D

G3DSA:1.10.10.60. Homeodomain-rel. 1 hit.

Pfam

PF00046. Homeobox. 1 hit.
PF00157. Pou. 1 hit.
[Graphical view]

PRINTS

PR00029. OCTAMER.
PR00028. POUDOMAIN.

ProDom

PD000010. Homeobox. 1 hit.
PD000583. POU. 1 hit.
[Graphical view] [Entries sharing at least one domain]

SMART

SM00389. HOX. 1 hit.
SM00352. POU. 1 hit.
[Graphical view]

PROSITE

PS00027. HOMEOBOX_1. 1 hit.
PS50071. HOMEOBOX_2. 1 hit.
PS00035. POU_1. 1 hit.
PS00465. POU_2. 1 hit.
PS51179. POU_3. 1 hit.
[Graphical view]

ProtoNet

Search...

Other Resources

NextBio

21101.

SOURCE

Search...

Entry information

Entry name

PO2F2_HUMAN

Accession

Primary (citable) accession number: P09086
Secondary accession number(s): Q16648, Q7M4M8, Q9BRS4

Entry history

Integrated into UniProtKB/Swiss-Prot:	November 1, 1988
Last sequence update:	January 23, 2007
Last modified:	November 3, 2009
This is version 123 of the entry and version 3 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation project

HPI (Human Proteome Initiative)

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.